Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
DX5A8D
|
|||
Drug Name |
Patritumab deruxtecan
|
|||
Synonyms |
HER3-DXd
Click to Show/Hide
|
|||
Drug Type |
Antibody drug conjugate
|
|||
Indication | Breast cancer [ICD-11: 2C60-2C65; ICD-10: C50, C79.51] | Phase 2 | [1] | |
Company |
Daiichi Sankyo Basking Ridge, NJ
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | DNA topoisomerase I (TOP1) | Target Info | Inhibitor | [2] |
NetPath Pathway | IL2 Signaling Pathway | |||
Panther Pathway | DNA replication | |||
Pathway Interaction Database | Caspase Cascade in Apoptosis | |||
WikiPathways | Integrated Pancreatic Cancer Pathway |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT05865990) Multicenter, Single-arm, 3 Cohort, Phase II Trial of HER3-DXd in Patients With Active Brain Metastases From Metastatic Breast Cancer and Non-small Cell Lung Cancer, and in Patients With Leptomeningeal Disease From Advanced Solid Tumors. U.S.National Institutes of Health. | |||
REF 2 | Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer. Cancer Discov. 2022 Jan;12(1):74-89. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.